Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsFrontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Fear of Movement, Central Sensitization May Worsen Outcomes in Gout
FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026
FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease
Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life
1.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
2.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
AI could help improve early detection of interval breast cancers
5.
Study identifies new target for obesity-related breast cancer
1.
Benefits of Neutrophilia: Harnessing the Power of White Blood Cells to Promote Health and Well-Being
2.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
3.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
4.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
5.
The Impact of Microadenoma on Hormonal Health
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge